Clinical Study of Amphotericin B and Voriconazole Induction Therapy Combined with Itraconazole Consolidation Therapy in the Treatment of Acquired Immune Deficiency Syndrome Patients with Talaromycosis Marneffei

LI Jinzhuo; LI Xiaoyun; YAN Ruqing; LI Fan; LIU Yanfei

doi:10.14009/j.issn.1672-2124.2022.05.018

您当前的位置：

首页 >

文章列表页 >

Clinical Study of Amphotericin B and Voriconazole Induction Therapy Combined with Itraconazole Consolidation Therapy in the Treatment of Acquired Immune Deficiency Syndrome Patients with Talaromycosis Marneffei

更新时间：2022-10-08

- Clinical Study of Amphotericin B and Voriconazole Induction Therapy Combined with Itraconazole Consolidation Therapy in the Treatment of Acquired Immune Deficiency Syndrome Patients with Talaromycosis Marneffei
- Vol. 22, Issue 5, Pages: 592-594(2022)
- 作者机构：
  
  1. 贺州市人民医院药学部
  2. 贺州市人民医院感染科
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2022.05.018
  CLC： R519;R512.91
- Published：2022，
扫描看全文
LI Jinzhuo, LI Xiaoyun, YAN Ruqing, et al. Clinical Study of Amphotericin B and Voriconazole Induction Therapy Combined with Itraconazole Consolidation Therapy in the Treatment of Acquired Immune Deficiency Syndrome Patients with Talaromycosis Marneffei. [J]. 22(5):592-594(2022)
DOI：

LI Jinzhuo, LI Xiaoyun, YAN Ruqing, et al. Clinical Study of Amphotericin B and Voriconazole Induction Therapy Combined with Itraconazole Consolidation Therapy in the Treatment of Acquired Immune Deficiency Syndrome Patients with Talaromycosis Marneffei. [J]. 22(5):592-594(2022) DOI： 10.14009/j.issn.1672-2124.2022.05.018.

摘要

目的：比较两性霉素B与伏立康唑诱导治疗分别联合伊曲康唑巩固治疗用于艾滋病(AIDS)合并马尔尼菲篮状菌病(TSM)患者的有效性和安全性。方法：选取2018年12月至2021年3月于该院就诊的AIDS合并TSM患者180例，基于随机数字表法分为两性霉素B组与伏立康唑组，每组90例。两性霉素B组患者采用两性霉素B诱导治疗联合伊曲康唑巩固治疗，伏立康唑组患者采用伏立康唑诱导治疗联合伊曲康唑巩固治疗，观察两组患者的临床疗效、血常规和肝肾功能。结果：两性霉素B组患者的临床总有效率为94.44%(85/90)

伏立康唑组为93.33%(84/90)

两组的差异无统计学意义(P>0.05)。两组患者治疗前、治疗后的白细胞计数、血小板计数、血红蛋白、天冬氨酸转氨酶和丙氨酸转氨酶水平比较，差异均无统计学意义(P>0.05)。治疗前，两组患者血肌酐、胱抑素C水平比较，差异均无统计学意义(P>0.05);治疗后，两性霉素B组患者的血肌酐、胱抑素C水平明显高于伏立康唑组，差异均有统计学意义(P<0.05)。结论：两性霉素B与伏立康唑诱导治疗分别联合伊曲康唑巩固治疗用于AIDS合并TSM患者的有效性和肝功能损害情况相当，但伏立康唑对患者肾功能的损害更小。

Abstract

OBJECTIVE: To compare the efficacy and safety of amphotericin B and voriconazole induction therapy combined with itraconazole consolidation therapy in the treatment of acquired immune deficiency syndrome（AIDS） patients with talaromycosis marneffei（TSM）. METHODS: A total of 180 AIDS patients with TSM admitted into the hospital from Dec. 2018 to Mar. 2021 were extracted to be divided into the amphotericin B group and voriconazole group via the random number table method

with 90 patients in each group. Amphotericin B group was treated with amphotericin B induction therapy combined with itraconazole consolidation therapy

while voriconazole group received voriconazole induction therapy combined with itraconazole consolidation therapy. The clinical efficacy

blood routine

liver and kidney functions of two groups were observed. RESULTS: The total clinical effective rate of amphotericin B group was 94.44%（85/90）

and that of voriconazole group was 93.33%（84/90）

the difference was not statistically significant（P>0.05）. There was no significant difference in the levels of white blood cell count

platelet count

hemoglobin

aspartate aminotransferase and alanine aminotransferase between two groups before and after treatment（P>0.05）. Before treatment

there was no significant difference in serum levels of creatinine and cystatin C between two groups（P>0.05）; after treatment

the serum levels of creatinine and cystatin C in the amphotericin B group were significantly higher than those of the voriconazole group

the difference was statistically significant（P<0.05）. CONCLUSIONS: The effectiveness and liver function damage of amphotericin B and voriconazole induction therapy combined with itraconazole consolidation therapy for AIDS patients with TSM are comparable

yet voriconazole causes less liver function damage in patients.

关键词

伏立康唑两性霉素B马尔尼菲篮状菌病艾滋病

Keywords

VoriconazoleAmphotericin BTalaromycosis marneffeiAcquired immune deficiency syndrome

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Therapeutic Drug Monitoring and Influencing Factors of Voriconazole in Patients with Acquired Immunodeficiency Syndrome Complicated with Fungal Infection

Comparison of Efficacy and Safety Between Domestic and Imported Voriconazole in the Treatment of Pulmonary Fungal Infection After Renal Transplantation

Symptom Characteristics and Related Factors of Mental Disorders Induced by Voriconazole

Application of Voriconazole in Patients with Malignant Hematological Disease and Invasive Fungal Infection

Related Author

ZHANG Xiaoying

YE Zhenjie

YU Xiaoling

WU Lingjie

ZHENG Ling

SU Ying

JIN Pengfei

XI Na

Related Institution

Clinical Research Center for Phase Ⅰ, Mengchao Hepatobiliary Hospital of Fujian Medical University

Dept. of Pharmacy,the Eighth Medical Center of Chinese PLA General Hospital

Dept. of Pharmacy,Beijing Hospital/National Center of Gerontology

Dept.of Respiratory Medicine,Nanping First Hospital Affiliated to Fujian Medical University

Dept.of Health Outpatient Service,Centers for Disease Control of Fujian Nanping

⁰